Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. KALA
stocks logo

KALA

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.320
-81.61%
--
--
-0.170
-87.94%
--
--
-0.120
-92.98%
Estimates Revision
The market is revising No Change the revenue expectations for KALA BIO, Inc. (KALA) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -93.37%.
EPS Estimates for FY2025
Revise Downward
down Image
-10.1%
In Past 3 Month
Stock Price
Go Down
down Image
-93.37%
In Past 3 Month
Wall Street analysts forecast KALA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KALA is 1.50 USD with a low forecast of 1.50 USD and a high forecast of 1.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast KALA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KALA is 1.50 USD with a low forecast of 1.50 USD and a high forecast of 1.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
2 Hold
0 Sell
Hold
Current: 0.964
sliders
Low
1.50
Averages
1.50
High
1.50
Current: 0.964
sliders
Low
1.50
Averages
1.50
High
1.50
Mizuho
Outperform
to
Neutral
downgrade
$30
2025-09-30
Reason
Mizuho
Price Target
$30
2025-09-30
downgrade
Outperform
to
Neutral
Reason
Mizuho downgraded Kala Bio to Neutral from Outperform with a price target of $1.50, down from $30. The firm cites yesterday's negative Phase 2 results for the company's lead asset KPI-012 for the downgrade. Mizuho is "very disappointed" by the data and has been unable to connect with management. The analyst removed KPI-012 Kala's model and downgraded the shares.
LifeSci Capital
Outperform -> Market Perform
downgrade
2025-09-29
Reason
LifeSci Capital
Price Target
2025-09-29
downgrade
Outperform -> Market Perform
Reason
LifeSci Capital downgraded Kala Pharmaceuticals to Market Perform from Outperform and removed the firm's price target after the company announced that its CHASE Phase 2b clinical trial of KPI-012 for the treatment of persistent corneal epithelial defect did not meet its primary endpoint and that the company plans to cease development of KPI-012 and its mesenchymal stem cell secretome platform based on the CHASE trial results.
Mizuho
Graig Suvannavejh
downgrade
2025-09-29
Reason
Mizuho
Graig Suvannavejh
Price Target
2025-09-29
downgrade
Reason
Mizuho analyst Graig Suvannavejh expects "material weakness" in Kala Pharmaceuticals shares today after the company announced that KPI-012 failed to achieve all primary and secondary end points in its Phase 2a study in persistent corneal epithelial defect. Kala shares shared no data details and is not hosting a call which is disappointing, the analyst tells investors in a research note. The stock in morning trading is down 90%, or $17.14, to $1.91.
H.C. Wainwright
Yi Chen
Buy -> Neutral
downgrade
2025-09-29
Reason
H.C. Wainwright
Yi Chen
Price Target
2025-09-29
downgrade
Buy -> Neutral
Reason
H.C. Wainwright analyst Yi Chen downgraded Kala Bio to Neutral from Buy without a price target.
H.C. Wainwright
H.C. Wainwright
upgrade
$12 -> $35
2025-09-17
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$12 -> $35
2025-09-17
upgrade
Reason
H.C. Wainwright raised the firm's price target on Kala Pharmaceuticals to $35 from $12 and keeps a Buy rating on the shares ahead of the CHASE trial readout, which is expected in late September. The firm increased the probability of approval for KPI-012 to 35%.
Oppenheimer
Andreas Argyrides
Outperform
upgrade
$15 -> $33
2025-09-11
Reason
Oppenheimer
Andreas Argyrides
Price Target
$15 -> $33
2025-09-11
upgrade
Outperform
Reason
Oppenheimer analyst Andreas Argyrides raised the firm's price target on Kala Pharmaceuticals to $33 from $15 and keeps an Outperform rating on the shares. Shares of Kala have soared since the summer up +222% vs. +10% XBI in anticipation of the Phase 2b readout of KPI-012 in PCED later this month. The firm sees meaningful upside from positive results that would establish KPI-012 as the only therapy addressing the broad 100,000 PCED market. Oppenheimer sees a high likelihood KPI-12 shows a significant treatment effect based on KPI-012's multifactorial mechanism that addresses multiple pathways that promote wound healing; promising Phase 1b results that show rapid PCED healing in 6/8 patients; and a carefully executed Phase 2b trial designed to mitigate placebo response. Even with the recent upward move in the stock, the firm is a buyer into strength ahead of the upcoming readout.
See All Ratings

Valuation Metrics

The current forward P/E ratio for KALA BIO Inc (KALA.O) is -1.32, compared to its 5-year average forward P/E of -1.49. For a more detailed relative valuation and DCF analysis to assess KALA BIO Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.49
Current PE
-1.32
Overvalued PE
-0.31
Undervalued PE
-2.68

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.56
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.71
Undervalued EV/EBITDA
-1.83

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
5.52
Current PS
0.00
Overvalued PS
15.04
Undervalued PS
-3.99
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 177.3% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 177.3% over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

KALA News & Events

Events Timeline

(ET)
2025-12-04
11:00:00
Kala Bio to Issue 10 Million Shares at $1.00 Each
select
2025-12-01 (ET)
2025-12-01
07:18:00
KALA BIO Enters $6M Securities Purchase Agreement with Investor David E. Lazar
select
2025-09-29 (ET)
2025-09-29
13:25:00
H.C. Wainwright Lowers Kala Bio Rating to Neutral Following CHASE Trial Setback
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.5
12-04SeekingAlpha
PinnedKALA BIO Plans to Secure $10 Million Through Registered Direct Offering

  • Stock Offering Announcement: KALA BIO has entered into agreements to sell 10,000,000 shares of its common stock at $1.00 per share in a registered direct offering, expected to close around December 5, 2025.

  • Use of Proceeds: The company anticipates gross proceeds of approximately $10 million, which will be used to repay debt and for general corporate purposes.

  • Current Stock Performance: Following the announcement, KALA BIO's stock price increased by 14.59%, reaching $1.06.

  • Recent Challenges: KALA BIO previously faced a significant decline in stock value, dropping 92% after a phase 2 trial failure for a drug targeting an eye condition.

[object Object]
Preview
8.5
00:12 AMNewsfilter
KALA BIO Secures $10 Million by Issuing 10 Million Shares at $1 Each
  • Financing Size: KALA BIO announced the issuance of 10 million shares at $1 each, expected to raise approximately $10 million, which will provide essential funds for debt repayment and general corporate purposes.
  • Transaction Structure: The financing is conducted via a registered direct offering, anticipated to close around December 5, 2025, indicating the company's strategic flexibility in capital raising under current market conditions.
  • Underwriter Role: H.C. Wainwright & Co. serves as the exclusive placement agent for this offering, reflecting the company's professional relationships in capital markets, which may enhance the efficiency and success of future financing efforts.
  • Strategic Use: KALA BIO intends to use the net proceeds for debt repayment, which not only aids in improving its financial condition but also provides funding support for future R&D and market expansion, thereby strengthening its competitive position in the ophthalmic biopharmaceutical sector.
[object Object]
Preview
4.5
12-04Benzinga
US Stocks Rise; Dollar General's Shares Surge Following Positive Earnings Report

  • U.S. Stock Market Performance: U.S. stocks saw a slight increase, with the Dow Jones up 0.1%, NASDAQ rising 0.01%, and S&P 500 gaining 0.1% on Thursday. Financial shares rose by 0.4%, while health care stocks fell by 0.6%.

  • Dollar General's Strong Earnings: Dollar General's shares surged over 7% after reporting better-than-expected third-quarter earnings of $1.28 per share and raising its FY25 guidance above estimates.

  • Notable Stock Movements: Polyrizon Ltd. shares skyrocketed 134% following positive preclinical test results, while Genesco Inc. shares plummeted 28% after disappointing financial results and lowered guidance.

  • Global Market Trends: European shares rose, with the eurozone's STOXX 600 up 0.5%, and Asian markets mostly closed higher, led by Japan's Nikkei gaining 2.33%. U.S. initial jobless claims decreased by 27,000 to 191,000.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is KALA BIO Inc (KALA) stock price today?

The current price of KALA is 0.964 USD — it has increased 4.22 % in the last trading day.

arrow icon

What is KALA BIO Inc (KALA)'s business?

KALA BIO, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the research, development, and commercialization of therapies for rare and severe diseases of the eye. The Company’s biologics-based investigational therapies utilize its proprietary mesenchymal stem cell secretome (MSC-S) platform. The Company’s product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biocfactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing, which is an underlying etiology of multiple severe ocular diseases; KPI-014 specific for inherited retinal degenerative diseases. KPI-012 is in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing. The Company is also engaged in the development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases.

arrow icon

What is the price predicton of KALA Stock?

Wall Street analysts forecast KALA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KALA is 1.50 USD with a low forecast of 1.50 USD and a high forecast of 1.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is KALA BIO Inc (KALA)'s revenue for the last quarter?

KALA BIO Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is KALA BIO Inc (KALA)'s earnings per share (EPS) for the last quarter?

KALA BIO Inc. EPS for the last quarter amounts to -1.07 USD, decreased -44.56 % YoY.

arrow icon

What changes have occurred in the market's expectations for KALA BIO Inc (KALA)'s fundamentals?

The market is revising No Change the revenue expectations for KALA BIO, Inc. (KALA) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -93.37%.
arrow icon

How many employees does KALA BIO Inc (KALA). have?

KALA BIO Inc (KALA) has 38 emplpoyees as of December 05 2025.

arrow icon

What is KALA BIO Inc (KALA) market cap?

Today KALA has the market capitalization of 7.91M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free